Page 6 - Scientific Library

Autologous tumour cell vaccines vs. dendritic cell vaccines: What's best, and why?

Understanding the best approach for tumour vaccinations is of growing importance in the personalized cancer immunotherapy

Recombinant protein expression and purification for therapeutic development or for in vitro studies can sometimes be a real challenge. It requires huge investments in both time

When doing WBs, IFs or IHCs, we normally pay a lot of attention to the primary antibody that should be chosen. We look at the datasheet, we check that the primary antibody has been validated for the species

Antibody generation raises a number of questions... what is the difference between their classes, forms and types? And how do recombinant monoclonal antibodies (rAbs) overcome the drawbacks

Tetramethylbenzidine (TMB) is a classic substrate for peroxidase activity that is used for microwell plate analysis such as an ELISA test. A quantitative color change from yellow to

I just want to briefly outline in this post the power of antibody microarray when it comes to time and cost saving as well as versatility. Whether you want to do multiple profiling or

Developing new therapeutic agents to boost the immune system and avoid the escape of diseased cells from the natural defenses is the common goal of all researchers in Immunotherapy. To greatly reduce time

When it comes to proteomics and broad protein profiling (and/or quantification), two main technologies come to mind: Mass Spectrometry and Antibody Arrays. Rather than opposing each other,

Thanks to its capability to recruit the natural protein degradation system of a cell, PROTACs (PROteolysis TArgeting Chimera) appears as a very promising

Multiplex protein assays allow multiple targets quantification in a single sample, a bit like performing up to 40 different ELISAs in one go. Outsourcing Multiplex Protein Quantification projects

For all species, classes or size (FL vs. fragments)

Whatever the type of antibody production (hybridoma or recombinant protein production

In new drug development pipelines, there is an increasing trend to switch from "small" to "large" molecules (also known as biologics). While the FDA guidance was quite specific with their recommendations